Future Network Talks #20

- in collaboration with GGL Gießen & MPI Bad Nauheim-

Dr. Lars Robbel, Director, Bioanalytical Sciences & Elisa DiNicola, Senior Talent Acquisition Partner
CSL-Behring Innovation

Recombinant technology is one of CSLs key scientific platforms for the development of novel therapeutics that address unmet patient needs. The Biopharmaceutical Product Development organization has recently implemented automation platforms (i.e. multiple liquid handlers and bioanalytical devices connected by a robot track system) to further augment development activities for these recombinant molecules. The automation platforms (one located in Marburg) are specifically designed for micro-scale Downstream Purification process development and related bioanalytical workflows to measure relevant quality attributes. Here we present CSLs QbD-driven approach to bioprocess development, utilization of novel technologies to enhance development endeavors and CSLs vision of the Lab of the Future.

About the speaker: Lars joined CSL in 2011 starting as a Scientist in Preclinical R&D. He then took over responsibility for shaping a team focused on bioanalytical characterization of recombinant molecules. After heading a dedicated USP/DSP Process Development team he currently leads the Bioanalytical Sciences Organization in Marburg, focused on delivery of data for the development and characterization of novel recombinant and viral vector-based biotherapies.
Lars is passionate about Lab Automation and Digital Transformation that synchronizes physical and digital infrastructures to gain efficiency for accelerated product development. Lars holds a PhD in Biochemistry from Marburg University.